|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
IMMUNOBIOLOGY
From the Department of Microbiology and Immunology,
Medical University of South Carolina, Charleston, SC, and the
Departments of Pathology and Cell Biology and Kaplan Cancer Center, New
York University School of Medicine, New York, NY.
Crry is a rodent membrane-bound inhibitor of complement activation
and is a structural and functional analog of the human complement
inhibitors decay-accelerating factor and membrane cofactor protein. We
found previously that expression of rat Crry on a human tumor cell line
enhances tumorigenicity in nude rats. In this study, we investigated
the effect that rat Crry expressed on tumor cells has on rat
cell-mediated cytotoxicity and antibody-dependent cell-mediated
cytotoxicity (ADCC). The expression of rat Crry on the surface of
different human tumor cell lines inhibited ADCC mediated by rat natural
killer (NK) cells. C3 opsonization is known to enhance NK
cell-mediated cytolysis, and a potential mechanism for Crry-mediated
inhibition of NK cell lysis is through Crry modulation of C3 deposition
on target cells. However, the transfection of tumor cell lines with
Crry enhanced their resistance to NK cell-mediated lysis in the
absence of exogenous complement. The resistance of Crry-expressing
tumor cells to NK cell-mediated ADCC could be reversed by treatment
with anti-Crry F(ab)2. In addition, anti-Crry
F(ab)2 enhanced the susceptibility of 13762 rat mammary
adenocarcinoma cells (that endogenously express Crry) to ADCC mediated
by allogeneic rat NK cells in the absence of added complement. We found
no evidence that rat NK cells were a source of complement for target
cell deposition during the in vitro cytolysis assay. These data suggest
a novel function for rat Crry in tumor immune surveillance that may be
unrelated to complement inhibition.
(Blood. 2002;100:3304-3310) Complement activation leads to the generation of C3
convertases that cleave serum C3 into C3a and C3b, the latter of which binds covalently to the activating surface and leads to the further generation of C3 convertase (thus resulting in amplification of the
cascade). The activation product C3b is rapidly degraded at the cell
surface by proteases with the aid of cofactors to yield iC3b and
further degradation products. iC3b can no longer function in the
activation of complement, but it is a ligand for complement receptor 3 (CR3, CD11b/CD18) found on phagocytes and NK cells, and iC3b
opsonization of target cells can promote and enhance cell-mediated
cytotoxicity.1-5 iC3b opsonization alone is not usually
sufficient to activate a cell-mediated cytolytic reaction against tumor
cells, unless a second distinct lectin domain specific for Normal and tumor cells are protected from complement by membrane-bound
complement inhibitory proteins. In humans, decay-accelerating factor
(DAF) and membrane cofactor protein (MCP) are the most important
proteins for controlling complement activation and amplification of the
cascade. CD59 is a different class of complement inhibitor that acts
later in the pathway and inhibits assembly of the terminal cytolytic
membrane attack complex. Various studies have reported an up-regulation
of complement inhibitors on tumor cells,8-11 implying that
complement inhibition may play a role in tumor escape from immune
system-mediated clearance. An inhibitor of complement activation
termed Crry is expressed on rodent, but not human, cell membranes. Crry
is broadly distributed and is a functional and structural analog of
human DAF and MCP.12-15 Rodent cells also express DAF and
MCP homologues, although the tissue distribution of MCP is
restricted.16-18
We are studying the role of complement inhibitory proteins in
facilitating tumor growth and the rat is an important model for
studying tumor immunology and immune effector mechanisms, especially
with regard to complement. Human complement inhibitory proteins are
species selective and therefore we have been using human tumor cell
lines transfected with rat complement inhibitors to study complement in
rat models of human cancer. We have shown that the expression of rat
Crry, but not rat CD59, on a human breast tumor cell line (MCF7)
significantly enhances tumorigenicity in nude rats.19
Crry, but not CD59, will inhibit C3 deposition, and our finding
suggested a role for C3 opsonization and cell-mediated cytotoxicity in
the modulation of tumor growth in this model. In this context, natural
killer (NK) cells and phagocytes are thought to play an important role
in immune resistance to tumors. Therefore, we investigated the effect
of rat Crry on rat cell-mediated cytolytic activity. We found that rat
Crry expression on target cells lowered their susceptibility to rat NK
cell-mediated ADCC in the presence of a complement source. This effect
may be due to Crry-mediated modulation of C3 deposition. However, we
found that Crry also inhibited rat NK cell-mediated ADCC in the
absence of exogenous complement, and our data indicate a novel function for rat Crry. These findings share some similarities to data previously reported for human DAF in which DAF was found to inhibit cytotoxicity of human NK cells when incorporated into target or NK cell
membranes.20
Cells
Antibodies
Transfection of tumor cell lines cDNA encoding rat CD59 and rat Crry were the gifts of Drs B. P. Morgan and H. Okada, respectively. cDNA encoding mouse Crry was the gift of Dr M. V. Holers. Rat CD59 was subcloned into the multiple cloning sites of the mammalian expression vector pCDNA3, and rat and mouse Crry cloned into pCDNA3.1 (Invitrogen, Carlsbad, CA). DNA was transfected into 50% to 75% confluent LAN-1, MCF7, or SKBR3 cells using Lipofectamine Plus according to the manufacturer's instructions (Life Technologies, Grand Island, NY). Stably transfected cells were selected following the cultivation of cells in the presence of G418 (PCDNA3) or zeocin (PCDNA3.1). Populations of cells expressing uniform levels of either rat CD59, rat Crry, or mouse Crry were isolated by several rounds of cell sorting using either anti-rat CD59 (mAb 6D1), anti-rat Crry (mAb 512), or anti-mouse Crry (mAb5D5) as described previously.23 Expression of Crry on transfected cells lines and the 13762 cell line was analyzed by flow cytometry as described.23Preparation of effector cells Except where indicated, all cytotoxocity assays were performed using effector cells isolated from Sprague Dawley rats. Sprague Dawley, Wistar Kyoto, or Fisher 344 rats (Taconic Farms, Germantown, NY) were treated with 10 mg/kg poly IC (Calbiochem, San Diego, CA). After 24 hours, rats were killed and their spleens removed. Splenocytes were gently isolated using a plunger and then passed through a 70-µm filter, washed, and isolated by low-speed centrifugation through Ficoll as described. B cells were depleted by incubation with Biomag magnetic beads conjugated to goat anti-rat IgG (PerSeptive Biosystems, Framingham, MA). After applying a magnet for 10 minutes, supernatants were removed and reapplied to the magnet 2 more times. Cells were then washed by centrifugation and resuspended in RPMI 1640. For NK cell depletion, splenocyte preparations were incubated (4°C for 30 minutes) with mouse anti-rat CD161 (Serotec, Raleigh, NC), washed and further incubated (4°C for 30 minutes) with magnetic beads conjugated to goat anti-mouse IgG (Dynall, Lake Success, NY). NK cells were then removed by applying a magnet. For NK cell purification, splenocyte preparations were incubated with mouse anti-rat CD4, CD8, ED1, and B-cell antigen (4°C for 30 minutes) (Serotec), washed, and further incubated (4°C for 30 minutes) with magnetic beads conjugated to goat anti-mouse IgG. A magnet was applied and NK cells were isolated and washed by centrifugation in phosphate-buffered saline (PBS). Preparations were checked for appropriate depletions by flow cytometric analysis. Mouse NK cells were purified from splenocyte preparations using anti-NK cell mAb DX5-coated microbeads and LS type separation columns on a MACS separator according to manufacturer's instructions (Miltenyi Biotec, Auburn, CA). Mouse splenocytes were prepared as described above for rat splenocytes. Purified rat and mouse NK cell preparations were checked by flow cytometry.Cytolysis assays Target cells were detached from plasticware with versene (Gibco BRL, Grand Island, NY), washed twice, and preloaded with sodium 51Cr (Amersham, Arlington Heights, IL) at 0.1 mCi (3.7 MBq)/106 cells for 90 minutes at 37°C. Cells were then washed 3 times in complete media (see above) and resuspended to 1 × 106/mL. If indicated, target cells were then incubated with appropriate opsonizing antibody for 30 minutes at 4°C. Antibody incubations were done using anti-membrane rabbit polyclonal antisera (anti-MCF7 and anti-SKBR3) at a 10% final antiserum concentration, or with anti-GD2 mAb 3F8 at 25 µg/mL (for GD2-positve LAN-1 cells). In some experiments, C6-deficient rat serum was added at time of antibody incubations (10% final concentration) as a source of exogenous complement. C6-deficient serum was used to prevent assembly of cytolytic MAC, but permit C3 deposition. In Crry-blocking experiments, target cells were incubated with anti-rat Crry F(ab)2 fragments at indicated concentrations (30 minutes/4°C) before the addition of opsonizing antibody. Following all antibody incubations, cells were washed and incubated with effector cells (5000 cells/well in 96-well plate) for 4 hours at 37°C/5% CO2. Lysis was determined by 51Cr release assay as described.20 For negative controls, target cells were incubated with media alone, and for maximal lysis controls target cells were incubated with 10% SDS. Rat and mouse NK-susceptible YAC1 cells were used as controls for NK cell activity in these assays.C3 assays To determine whether NK cells produced C3, and if so whether C3 could bind to MCF7 target cells, NK cells were incubated in microtiter plate wells at 37°C/5% CO2 in medium at the concentration used in cytolysis assays (above). The wells were first coated with either bovine serum albumin (BSA) or purified anti-MCF7 antibodies (10 µg/mL, 4 hours at room temperature). After 0, 4, or 12 hours, culture supernatant was collected. C3 in culture supernatant was assayed by enzyme-linked immunosorbent assay (ELISA) using a standard techniques.22 Briefly, microtiter plates were coated with goat anti-rat C3 antibody (30 µg/mL overnight at 4°C), and plates then blocked with 2% skimmed milk in PBS. Culture supernatant was incubated in wells for 1 hour at room temperature, and bound C3 detected by means of goat anti-rat C3 conjugated to HRP and chromogenic substrate. Mouse C3 was similarly assayed using goat anti-mouse C3 antibodies. Normal pooled rat or mouse serum was used as standard. Deposition on NK cell-derived C3 MCF7 target cells was assayed by flow cytometry. NK cell culture supernatant was incubated with anti-MCF7 opsonized target cells for 1 hour at 37°C. Cells were washed and analyzed by flow cytometry23 after incubation with FITC-conjugated goat anti-rat or anti-mouse C3. For a positive control, antibody opsonized cells were incubated with C6-deficient rat serum (10% final concentration).
Expression of rat Crry on human tumor target cells reduces their susceptibility to rat NK lysis The human breast cancer cell line MCF7 was transfected with rat Crry and a cell population stably expressing the cell surface recombinant protein was isolated by fluorescence activated cell sorting (Figure 1). MCF7 and MCF7/Crry cells were assayed for susceptibility to cell-mediated lysis in vitro using rat splenocytes depleted of B cells. At an effector-to-target (E/T) ratio of 100:1, less than 20% of MCF7 cells were lysed, but lysis was significantly enhanced by the addition of rabbit anti-MCF7 antibody (Figure 2A). When a complement source was added to MCF7 target cells in the presence of specific antibody, lysis of MCF7 was further enhanced. Rat C6-deficient serum was used as a complement source to allow the generation of C3 convertase and C3 deposition on MCF7, but not the formation of the cytolytic membrane attack complex. C6-deficient serum alone (ie, in the absence of added anti-MCF7 antibody) also slightly enhanced cell-mediated lysis, but flow cytometry revealed the presence of "natural" antibodies reactive to MCF7 in C6-deficient rat serum that likely contribute to the observed enhancement of lysis. Crry transfected MCF7 were significantly more resistant to ADCC than untransfected MCF7, even in the presence of a complement source (83% verses 9%) (Figure 2A). The very low level of natural cytotoxicity mediated by splenocyte preparations in the absence of specific antibody was not significantly inhibited by the expression of Crry on target MCF7 cells. Cytotoxicity of the rat splenocyte preparation was mediated by NK cells, since NK cell depletion in vitro resulted in complete abrogation of cell lysis. In addition, purified rat NK cells (Figure 2B) produced similar cytolytic profiles against MCF7 and Crry transfected MCF7 as did B-cell-depleted splenocyte preparations (Figure 2A). Stable expression of rat CD59 on MCF7 cells had no inhibitory effect on NK-mediated cytolysis (not shown), indicating that the isolation procedure did not select an unrelated trait affecting susceptibility to NK lysis.
Two other human tumor cell lines, SKBR3 (breast carcinoma) and LAN1
(neuroblastoma), were similarly transfected with rat Crry and their
susceptibility to NK-mediated lysis determined. These 2 cell lines were
also susceptible to NK-mediated ADCC and, similar to MCF7, expression
of rat Crry conferred resistance to NK-mediated ADCC (Figure
3). SKBR3 and LAN1 cell lines were
inherently more resistant than MCF7 to NK-mediated cytolysis in the
absence of specific antibody (SKBR3 was totally resistant; compare
Figures 2B, 3A-B), and the expression of Crry on these targets also had no detectable effect on natural NK-mediated cytolysis.
Anti-Crry F(ab)2 modulates NK inhibitory effects of Crry expression Further confirmation that rat Crry expressed on target cells can modulate NK cytotoxicity was obtained from experiments using anti-Crry F(ab)2 to block Crry-mediated NK inhibitory activity. Anti-Crry F(ab)2 increased susceptibility of Crry-expressing MCF7 to NK cell-mediated ADCC in a dose-dependent manner (Figure 4). Anti-Crry F(ab)2 had no significant effect on NK lysis of untransfected MCF7 either in the presence or absence of anti-MCF7 sensitizing antibody, indicating that the F(ab)2 preparation was not alone responsible for enhancing NK cell-mediated lysis. NK cell susceptibility of Crry-transfected LAN-1 was similarly enhanced by the addition of anti-Crry F(ab)2 (Figure 5). In these antibody blocking experiments, similar results were obtained with F(ab)2 preparations derived from either polyclonal or monoclonal anti-Crry antibodies. Data shown in Figure 4 were obtained using a polyclonal anti-Crry preparation together with a polyclonal anti-MCF7 sensitizing antibody. Data shown in Figure 5 were obtained using a monoclonal anti-Crry antibody (mAb 5I2) together with a monoclonal sensitizing antibody (anti-GD2 mAb 3F8). Both monoclonal14 and polyclonal (not shown) Crry F(ab)2 preparations block the complement inhibitory function of Crry.
Anti-Crry F(ab)2 enhances NK-mediated lysis of allogeneic but not syngeneic target cells We investigated whether Crry expressed endogenously on rat target cells may play a role in modulating cell-mediated cytotoxicity. First, the susceptibility of rat mammary adenocarcinoma 13762 cell line to ADCC mediated by either syngeneic or allogeneic splenocyte preparations was determined. 13762 cells express endogenous Crry (Figure 1) and CD59 (not shown). Not surprisingly, 13762 cells were completely resistant to lysis by syngeneic Fisher 344-derived splenocytes, both in the presence and absence of rabbit anti-13762 specific antibody (not shown). In contrast, 13762 cells were sensitive to ADCC mediated by allogeneic splenocyte preparations, but the percent lysis was low; specific cytolysis of splenocytes prepared from Sprague Dawley or Wistar Kyoto rats ranged between 8% (Figure 6) and 12% (not shown), respectively, at an E/T ratio of 100:1 in the presence of specific antibody. However, the susceptibility of 13762 cells to ADCC by allogeneic splenocytes was significantly enhanced by their preincubation with anti-Crry F(ab)2 from about 8% to 19% specific lysis (Figure 6). Anti-Crry had no significant effect on natural cell-mediated cytoxicity mediated by allogeneic splenocytes (Figure 6), and did not enhance ADCC mediated by syngeneic Fisher 344-derived splenocytes (not shown). Splenocyte preparations used in these experiments were depleted of B cells and, similarly as shown above with experiments using xenogeneic targets, the depletion of NK cells from splenocyte preparations completely abrogated lytic activity (data not shown).
Deposition of NK-derived C3 on target cells Crry inhibits complement activation and limits C3 deposition and opsonization of target cells. Although Crry inhibited NK-mediated ADCC in the absence of exogenously added complement (see above), it is possible that C3 synthesized by NK cells during the assay can become cleaved and deposited on the target cell, thus enhancing NK cytolysis. Crry expression on target cells could inhibit the deposition of NK-derived C3 and, therefore, potentially inhibit C3-enhanced NK-mediated cytolysis. In this context, it is known that human lymphocytes and NK cells synthesize C3.20,24 Therefore, we determined whether rat NK cells secrete C3. NK cell preparations were cultured the absence of target cells under assay conditions, and at various time points the culture supernatant was removed and assayed for C3 by ELISA. Since it is possible that the cross-linking of Fc receptors on rat NK cells mediated by antibody-coated target cells may induce C3 secretion, in some experiments Fc receptors were engaged on NK cells by incubating the NK cells in the presence of immobilized purified anti-MCF7 antibody (the same antibody used to sensitize MCF7 target cells to ADCC). The data in Table 1 show that rat NK cells secrete C3, and at levels similar to those reported for human NK cells.20 Interestingly, the presence of immobilized anti-MCF7 antibody caused an initial enhancement of C3 secretion. To determine whether C3 secreted by NK cells could opsonize target tumor cells, NK cell preparations were cultured for either 4 or 12 hours in the presence of immobilized anti-MCF7 antibody, the culture supernatant removed and added to antibody-sensitized MCF7 target cells. Target cells were then assayed for C3 deposition by flow cytometry. No C3 was detected on MCF7 target cells that were incubated in either 4- or 12-hour NK cell culture supernatant (Figure 7). The duration of NK cell cytolytic assay is 4 hours. Together these data indicate that rat NK cells produce C3, but not at levels sufficient to modulate ADCC.
The use of NK cells derived from C3-deficient mice would allow us to
more directly determine whether C3 produced by NK cells was involved in
modulating cytolysis. We therefore transfected MCF7 cells with mouse
Crry, isolated a stably expressing population, and determined the
effect of mouse Crry on mouse NK cell-mediated lysis. Surprisingly,
mouse Crry had no effect on cytolysis of MCF7 cells mediated by
purified mouse NK cells (Figure 8);
nevertheless, mouse NK cells did secrete C3 at similar levels to rat NK
cells, and no C3 was detected on MCF7 target cells that were incubated in 12-hour mouse NK cell culture supernatant (data not shown).
Innate recognition by NK cells is mediated by opposing effects of
various activation and inhibitory receptors that are less well defined
in the rat than in humans and mice (for review, see Lanier25 and Lanier26). In addition to
receptors involved in innate recognition, NK cells express CD16
(Fc Another activation receptor expressed on NK cells is complement
receptor 3 (CR3 or CD11b/CD18). The principal complement ligand for CR3
is iC3b, a C3 degredation product covalently bound to the cell surface
at a site of complement activation. Enhancement of phagocyte and NK
cell-mediated ADCC by complement opsonization of the target cell is
mediated via the iC3b/CR3 interaction.1-5 However,
although CR3 can mediate cell adhesion to tumor cells, the binding of
iC3b alone to CR3 does not trigger phagocyte or NK cell cytotoxicity. A
signaling mechanism to trigger cytolytic function is provided by the
membrane association of CR3 with Fc Our experiments show that expression of Crry inhibits NK-mediated target cell lysis in vitro, a phenotype which we suggest may be related to tumor escape from immune clearance in vivo. Since C3 opsonization of target cells is known to enhance NK-mediated ADCC, an inhibitor of complement activation expressed on a target cell might inhibit ADCC by limiting C3 deposition. Such an effect would inhibit target cell susceptibility to lysis. However, in the studies reported here, Crry expressed on target cell surfaces inhibited NK-mediated ADCC in the absence of exogenously added complement. There are 2 plausible mechanisms for this effect of Crry on NK cell lytic function. One possibility is that Crry may directly interact with an NK cell inhibitory receptor and regulate lytic function in spite of target cell recognition. There is currently no direct evidence to support this notion, but this possibility is plausible since DAF, a structurally and functionally related protein, is a cellular ligand for CD97, an activation-induced leukocyte receptor with no apparent link to the complement system.32,33 The biologic significance of CD97-DAF interaction is unknown. In addition, both DAF and Crry can also associate with other membrane proteins and both are involved in signal transduction.34,39 A second possible mechanism for the effect of Crry on NK cell cytotoxicity is that C3 secreted by the NK cells during the in vitro cytotolysis assay becomes bound to the target cells enhancing ADCC, and that the deposition of locally synthesized C3 on the target cell is inhibited by the expression of Crry. Supporting this notion are data demonstrating that human NK cells secrete C3 in vitro.20 Here we have shown that rat NK cells also secrete C3, but that NK-secreted C3 does not deposit on antibody opsonized target cells in detectable quantity. This argues against a role for C3 opsonization in the Crry-mediated inhibitory effect on NK cells, but we cannot rule out the possibility that NK cell C3 secretion is polarized resulting in a high local concentration of C3 at the site of NK target cell contact, as has been shown to occur for cytokine secretion and cytolysis of lytic granules. To determine whether C3 was involved in the Crry-NK interaction, we attempted to duplicate our findings using a mouse system. The use of NK cells derived from C3-deficient mice would have allowed us to directly address the role of C3 in NK lysis. However, transfection of human tumor cells with mouse Crry had no effect on their susceptibility to mouse NK lysis, although mouse NK cells did produce C3. The expression of rat Crry on xenogeneic targets had a negligible effect on rat NK cell-mediated cytoxicity in the absence of target cell-specific antibodies, although the human cell lines used as targets were relatively resistant to natural lysis mediated by either B-cell-depleted splenocyte preparations or purified NK cells. Thus, antibody opsonization of target cells may be required for complement activation and C3 deposition on target cells. In the absence of exogenous complement, in vitro activation of NK-derived C3 may occur by direct binding to the target cell and/or target cell-bound antibody,40,41 by proteolytic cleavage by lymphocyte-derived protease,42 or via classical pathway activation by NK synthesized complement proteins. In any case, in the tumor microenvironment in situ tumor cells would be expected to have substantial complement available owing to abundant vascularization. It is not immediately apparent why the haplotype of the NK cell should have an effect on ADCC (Figure 6) since there is no direct evidence that ADCC is major histocompatibility complex (MHC) restricted. It is possible that the result may reflect differences in expression levels of receptors or activity among the different NK cell haplotypes. Activation of NK cells is held in balance by various activation and inhibitory signals, and it is certainly conceivable that MHC molecules can contribute to this balance during NK cell-mediated ADCC. The rat is an important model for studying tumor immunology and immune effector mechanisms, and our findings are relevant to the interpretation of certain studies using rat models of cancer. An earlier study showed that human DAF inhibited the cytotoxicity of human NK cells.20 DAF has structural and functional similarities with Crry, and thus the phenomenon reported here with rat Crry and NK cells is likely of relevance to human immune mechanisms. On the other hand, we found that expression of mouse Crry on target cells did not effect their susceptibility to mouse NK cells. We were surprised by this result, but NK cells have multiple mechanisms of target cell recognition and further research is needed to define related mechanisms in the various systems. It is worthwhile noting that significant differences among human, rat, and mouse NK cell-mediated ADCC of tumor targets has been reported previously.43
Submitted October 18, 2001; accepted June 18, 2002.
Supported by Department of the Army grants DAMD17-01-1-0393 and DAMD12-99-1-9325 and by National Institutes of Health grant AI 34451.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Stephen Tomlinson, Medical University of South Carolina, Department of Microbiology and Immunology, BSB 201, 173 Ashley Ave, Charleston, SC 29425; e-mail: tomlinss{at}musc.edu.
1. Ramos OF, Kai C, Yefenof E, Klein E. The elevated natural killer sensitivity of targets carrying surface-attached C3 fragments require the availability of the iC3b receptor (CR3) on the effectors. J Immunol. 1988;140:1239-1243[Abstract]. 2. Wahlin B, Perlmann H, Perlmann P, Schreiber RD, Muller-Eberhard HJ. C3 receptors on human lymphocyte subsets and recruitment of ADCC effector cells by C3 fragments. J Immunol. 1983;130:2831-2836[Abstract]. 3. Becherer JD, Alsenz J, Servis C, Myones BL, Lambris JD. Cell surface proteins reacting with activated complement components. Complement Inflamm. 1989;6:142-165[Medline] [Order article via Infotrieve]. 4. Krauss JC, Poo H, Xue W, Mayo-Bond L, Todd RF III, Petty HR. Reconstitution of antibody-dependent phagocytosis in fibroblasts expressing Fc gamma receptor IIIB and the complement receptor type 3. J Immunol. 1994;153:1769-1777[Abstract]. 5. Ross GD. Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaMbeta2-integrin glycoprotein. Crit Rev Immunol. 2000;20:197-222[Medline] [Order article via Infotrieve].
6.
Wright SD, Silverstein SC.
Receptors for C3b and C3bi promote phagocytosis but not the release of toxic oxygen from human phagocytes.
J Exp Med.
1983;158:2016-2023 7. Vetvicka V, Thornton BP, Ross GD. Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J Clin Invest. 1996;98:50-61[Medline] [Order article via Infotrieve]. 8. Li L, Spendlove I, Morgan J, Durrant LG. CD55 is over-expressed in the tumour environment. Br J Cancer. 2001;84:80-86[CrossRef][Medline] [Order article via Infotrieve]. 9. Hofman P, Hsi BL, Manie S, Fenichel P, Thyss A, Rossi B. High expression of the antigen recognized by the monoclonal antibody GB24 on human breast carcinomas: a preventative mechanism of malignant tumor cells against complement attack? Breast Cancer Res Treat. 1994;32:213-219[CrossRef][Medline] [Order article via Infotrieve].
10.
Simon HG, Risse B, Jost M, Oppenheimer S, Kari C, Rodeck U.
Identification of differentially expressed messenger RNAs in human melanocytes and melanoma cells.
Cancer Res.
1996;56:3112-3117 11. Thorsteinsson L, O'Dowd GM, Harrington PM, Johnson PM. The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues. Apmis. 1998;106:869-878[Medline] [Order article via Infotrieve].
12.
Molina H, Wong W, Kinoshita T, Brenner C, Foley S, Holers VM.
Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1.
J Exp Med.
1992;175:121-129 13. Li B, Sallee C, Dehoff M, Foley S, Molina H, Holers VM. Mouse Crry/p65: characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF. J Immunol. 1993;151:4295-4305[Abstract]. 14. Takizawa H, Okada N, Okada H. Complement inhibitor of rat cell membrane resembling mouse Crry/p65. ji. 1994;152:3032-3038. 15. Funabashi K, Okada N, Matsuo S, Yamamoto T, Morgan BP, Okada H. Tissue distribution of complement regulatory membrane proteins in rats. Immunology. 1994;81:444-451[Medline] [Order article via Infotrieve]. 16. Tsujimura A, Shida K, Kitamura M, et al. Molecular cloning of a murine homologue of membrane cofactor protein (CD46): preferential expression in testicular germ cells. Biochem J. 1998;330:163-168. 17. Mead R, Hinchliffe SJ, Morgan BP. Molecular cloning, expression and characterization of the rat analogue of human membrane cofactor protein (MCP/CD46). Immunology. 1999;98:137-143[CrossRef][Medline] [Order article via Infotrieve]. 18. Miwa T, Nonaka M, Okada N, Wakana S, Shiroishi T, Okada H. Molecular cloning of rat and mouse membrane cofactor protein (MCP, CD46): preferential expression in testis and close linkage between the mouse Mcp and Cr2 genes on distal chromosome 1. Immunogenetics. 1998;48:363-371[CrossRef][Medline] [Order article via Infotrieve].
19.
Caragine TA, Okada N, Frey AB, Tomlinson S.
A tumor-expressed inhibitor of the early but not late lytic complement pathway enhances tumor growth in a rat model of human breast cancer.
Cancer Res.
2002;62:1110-1115 20. Finberg RW, White W, Nicholson-Weller A. Decay accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells. J Immunol. 1992;131:2913-2918[Abstract]. 21. Frey AB, Appleman LJ. Rat adenocarcinoma 13762 expresses tumor rejection antigens but tumor-bearing animals exhibit tumor-specific immunosupression. Clin Immunol Immunopathol. 1993;69:223-233[CrossRef][Medline] [Order article via Infotrieve]. 22. Harlow E, Lane D. Antibodies. A laboratory manual. New York: Cold Spring Harbor Laboratory; 1988.
23.
Yu J, Abagyan RA, Dong S, Gilbert A, Nussenzweig V, Tomlinson S.
Mapping the active site of CD59.
J Exp Med.
1997;185:745-753 24. Morgan BP, Gasque P. Extrahepatic complement biosynthesis: where, when and why? Clin Exp Immunol. 1997;107:1-7[CrossRef][Medline] [Order article via Infotrieve]. 25. Lanier LL. Activating and inhibitory NK cell receptors. Adv Exp Med Biol. 1998;452:13-18[Medline] [Order article via Infotrieve]. 26. Lanier LL. NK cell receptors. Annu Rev Immunol. 1998;16:359-393[CrossRef][Medline] [Order article via Infotrieve].
27.
Ravetch JV, Lanier LL.
Immune inhibitory receptors.
Science.
2000;290:84-89 28. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6:443-446[CrossRef][Medline] [Order article via Infotrieve]. 29. Zhou M, Todd RF III, van de Winkel JG, Petty HR. Cocapping of the leukoadhesin molecules complement receptor type 3 and lymphocyte function-associated antigen-1 with Fc gamma receptor III on human neutrophils: possible role of lectin-like interactions. J Immunol. 1993;150:3030-3041[Abstract]. 30. Stockl J, Majdic O, Pickl WF, Rosenkranz A, Prager E, Gschwantler E, Knapp W. Granulocyte activation via a binding site near the C-terminal region of complement receptor type 3 alpha-chain (CD11b) potentially involved in intramembrane complex formation with glycosylphosphatidylinositol-anchored Fc gamma RIIIB (CD16) molecules. J Immunol. 1995;154:5452-5463[Abstract].
31.
Zhou MJ, Brown EJ.
CR3 (Mac-1, alpha M beta 2, CD11b/CD18) and Fc gamma RIII cooperate in generation of a neutrophil respiratory burst: requirement for Fc gamma RIII and tyrosine phosphorylation.
J Cell Biol.
1994;125:1407-1416
32.
Hamann J, Vogel B, van Schijndel GM, van Lier RA.
The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF).
J Exp Med.
1996;184:1185-1189 33. Qian YM, Haino M, Kelly K, Song WC. Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55). Immunology. 1999;98:303-311[CrossRef][Medline] [Order article via Infotrieve]. 34. Shenoy-Scaria AM, Kwong J, Fujita T, Olszowy MW, Shaw AS, Lublin DM. Signal transduction through decay-accelerating factor: interaction of glycosyl-phosphatidylinositol anchor and protein tyrosine kinases p56lck and p59fyn 1. J Immunol. 1992;149:3535-3541[Abstract]. 35. Shibuya K, Abe T, Fujita T. Decay-accelerating factor functions as a signal transducing molecule for human monocytes. J Immunol. 1992;149:1758-1762[Abstract]. 36. Davis LS, Patel SS, Atkinson JP, Lipsky PE. Decay-accelerating factor functions as a signal transducing molecule for human T cells. J Immunol. 1988;141:2246-2252[Abstract].
37.
Parolini I, Sargiacomo M, Lisanti MP, Peschle C.
Signal transduction and glycophosphatidylinositol-linked proteins (lyn, lck, CD4, CD45, G proteins, and CD55) selectively localize in Triton-insoluble plasma membrane domains of human leukemic cell lines and normal granulocytes.
Blood.
1996;87:3783-3794
38.
Stefanova I, Horejsi V, Ansotegui IJ, Knapp W, Stockinger H.
GPI-anchored cell-surface molecules complexed to protein tyrosine kinases.
Science.
1991;254:1016-1019
39.
Fernandez-Centeno E, de Ojeda G, Rojo JM, Portoles P.
Crry/p65, a membrane complement regulatory protein, has costimulatory properties on mouse T cells.
J Immunol.
2000;164:4533-4542 40. Pangburn MK, Muller-Eberhard HJ. Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3. Ann NY Acad Sci. 1983;421:291-298[Medline] [Order article via Infotrieve]. 41. Kulics J, Rajnavolgyi E, Fust G, Gergely J. Interaction of C3 and C3b with immunoglobulin G. Mol Immunol. 1983;20:805-810[CrossRef][Medline] [Order article via Infotrieve]. 42. Ramos OF, Algarra I, Sarmay G, Yefenof E, Gergely J, Klein E. Lymphocytes stimulated by allogeneic B cell lines cleave the third component of complement and fix C3 fragments: their nonspecific lytic capacity is elevated against complement receptor type 2-carrying targets. J Immunol. 1989;142:217-223[Abstract]. 43. Bergman I, Basse PH, Barmada MA, Griffin JA, Cheung NK. Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors. Cancer Immunol Immunother. 2000;49:259-266[CrossRef][Medline] [Order article via Infotrieve].
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  E. Racila, B. K. Link, W.-K. Weng, T. E. Witzig, S. Ansell, M. J. Maurer, J. Huang, C. Dahle, A. Halwani, R. Levy, et al. A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma Clin. Cancer Res., October 15, 2008; 14(20): 6697 - 6703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Varela, M. Imai, C. Atkinson, R. Ohta, M. Rapisardo, and S. Tomlinson Modulation of Protective T Cell Immunity by Complement Inhibitor Expression on Tumor Cells Cancer Res., August 15, 2008; 68(16): 6734 - 6742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Imai, R. Ohta, J. C. Varela, H. Song, and S. Tomlinson Enhancement of Antibody-Dependent Mechanisms of Tumor Cell Lysis by a Targeted Activator of Complement Cancer Res., October 1, 2007; 67(19): 9535 - 9541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Elward, M. Griffiths, M. Mizuno, C. L. Harris, J. W. Neal, B. P. Morgan, and P. Gasque CD46 Plays a Key Role in Tailoring Innate Immune Recognition of Apoptotic and Necrotic Cells J. Biol. Chem., October 28, 2005; 280(43): 36342 - 36354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Miyagawa, T. Kubo, K. Matsunami, T. Kusama, K. Beppu, H. Nozaki, T. Moritan, C. Ahn, J. Y. Kim, D. Fukuta, et al. Delta-Short Consensus Repeat 4-Decay Accelerating Factor (DAF: CD55) Inhibits Complement-Mediated Cytolysis but Not NK Cell-Mediated Cytolysis J. Immunol., September 15, 2004; 173(6): 3945 - 3952. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
-glucan
on CR3 is ligated.
RIII), a low-affinity receptor for IgG that is responsible for
mediating ADCC in the absence of effective inhibition.